FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136570034> ?p ?o ?g. }

• W2136570034 endingPage "5538" @default.
• W2136570034 startingPage "5534" @default.
• W2136570034 abstract "Irinotecan and cisplatin (IP) significantly improved survival compared with etoposide and cisplatin (EP), in patients with extensive-stage small cell lung cancer (SCLC) in a previous Japan Clinical Oncology Group (JCOG) randomized trial. JCOG9903 was conducted to evaluate the safety of sequentially given IP following concurrent EP plus twice-daily thoracic irradiation (TRT) for the treatment of limited-stage SCLC (LSCLC).Between October 1999 and July 2000, 31 patients were accrued from 10 institutions. Thirty patients were assessable for toxicity, response, and survival. Treatment consisted of etoposide 100 mg/m(2) on days 1 to 3, cisplatin 80 mg/m(2) on day 1, and concurrent twice-daily TRT of 45 Gy beginning on day 2. The IP regimen started on day 29 and consisted of irinotecan 60 mg/m(2) on days 1, 8, and 15 and cisplatin 60 mg/m(2) on day 1, with three 28-day cycles.There were no treatment-related deaths. The response rate was 97% (complete response, 37%; partial response, 60%). Median overall survival was 20.2 months; 1-, 2-, and 3-year survival rates were 76%, 41%, and 38%, respectively. Of the 24 patients who started the IP regimen, 22 received two or more cycles. Hematologic toxicities of grade 3 or 4 included neutropenia (67%), anemia (50%), and thrombocytopenia (4%). Nonhematologic toxicities of grade 3 or 4 included diarrhea (8%), vomiting (8%), and febrile neutropenia (8%). Of the 20 patients with recurrence, none had local recurrence alone and only two had both local and distant metastasis as the initial sites of disease progression.IP following concurrent EP plus twice-daily TRT is safe with acceptable toxicities. A randomized phase III trial comparing EP with IP following EP plus concurrent TRT for LSCLC is ongoing (JCOG0202)." @default.
• W2136570034 created "2016-06-24" @default.
• W2136570034 creator A5003703815 @default.
• W2136570034 creator A5033435047 @default.
• W2136570034 creator A5034162457 @default.
• W2136570034 creator A5040839997 @default.
• W2136570034 creator A5045329864 @default.
• W2136570034 creator A5047714811 @default.
• W2136570034 creator A5050855780 @default.
• W2136570034 creator A5054539545 @default.
• W2136570034 creator A5055518358 @default.
• W2136570034 creator A5058549884 @default.
• W2136570034 creator A5059955082 @default.
• W2136570034 date "2005-08-01" @default.
• W2136570034 modified "2023-09-25" @default.
• W2136570034 title "Pilot Study of Concurrent Etoposide and Cisplatin Plus Accelerated Hyperfractionated Thoracic Radiotherapy Followed by Irinotecan and Cisplatin for Limited-Stage Small Cell Lung Cancer: Japan Clinical Oncology Group 9903" @default.
• W2136570034 cites W1885320430 @default.
• W2136570034 cites W1905406155 @default.
• W2136570034 cites W1952431753 @default.
• W2136570034 cites W1959962586 @default.
• W2136570034 cites W2014450005 @default.
• W2136570034 cites W2029409133 @default.
• W2136570034 cites W2073683299 @default.
• W2136570034 cites W2124353451 @default.
• W2136570034 cites W2160012348 @default.
• W2136570034 cites W2323020638 @default.
• W2136570034 cites W2341745217 @default.
• W2136570034 cites W2440995134 @default.
• W2136570034 cites W2605054432 @default.
• W2136570034 doi "https://doi.org/10.1158/1078-0432.ccr-04-1771" @default.
• W2136570034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16061870" @default.
• W2136570034 hasPublicationYear "2005" @default.
• W2136570034 type Work @default.
• W2136570034 sameAs 2136570034 @default.
• W2136570034 citedByCount "38" @default.
• W2136570034 countsByYear W21365700342012 @default.
• W2136570034 countsByYear W21365700342013 @default.
• W2136570034 countsByYear W21365700342014 @default.
• W2136570034 countsByYear W21365700342016 @default.
• W2136570034 countsByYear W21365700342017 @default.
• W2136570034 countsByYear W21365700342019 @default.
• W2136570034 countsByYear W21365700342020 @default.
• W2136570034 crossrefType "journal-article" @default.
• W2136570034 hasAuthorship W2136570034A5003703815 @default.
• W2136570034 hasAuthorship W2136570034A5033435047 @default.
• W2136570034 hasAuthorship W2136570034A5034162457 @default.
• W2136570034 hasAuthorship W2136570034A5040839997 @default.
• W2136570034 hasAuthorship W2136570034A5045329864 @default.
• W2136570034 hasAuthorship W2136570034A5047714811 @default.
• W2136570034 hasAuthorship W2136570034A5050855780 @default.
• W2136570034 hasAuthorship W2136570034A5054539545 @default.
• W2136570034 hasAuthorship W2136570034A5055518358 @default.
• W2136570034 hasAuthorship W2136570034A5058549884 @default.
• W2136570034 hasAuthorship W2136570034A5059955082 @default.
• W2136570034 hasBestOaLocation W21365700341 @default.
• W2136570034 hasConcept C121608353 @default.
• W2136570034 hasConcept C126322002 @default.
• W2136570034 hasConcept C141071460 @default.
• W2136570034 hasConcept C143998085 @default.
• W2136570034 hasConcept C2776694085 @default.
• W2136570034 hasConcept C2777063308 @default.
• W2136570034 hasConcept C2778119113 @default.
• W2136570034 hasConcept C2778239845 @default.
• W2136570034 hasConcept C2778850193 @default.
• W2136570034 hasConcept C2780259306 @default.
• W2136570034 hasConcept C2781413609 @default.
• W2136570034 hasConcept C526805850 @default.
• W2136570034 hasConcept C71924100 @default.
• W2136570034 hasConcept C90924648 @default.
• W2136570034 hasConceptScore W2136570034C121608353 @default.
• W2136570034 hasConceptScore W2136570034C126322002 @default.
• W2136570034 hasConceptScore W2136570034C141071460 @default.
• W2136570034 hasConceptScore W2136570034C143998085 @default.
• W2136570034 hasConceptScore W2136570034C2776694085 @default.
• W2136570034 hasConceptScore W2136570034C2777063308 @default.
• W2136570034 hasConceptScore W2136570034C2778119113 @default.
• W2136570034 hasConceptScore W2136570034C2778239845 @default.
• W2136570034 hasConceptScore W2136570034C2778850193 @default.
• W2136570034 hasConceptScore W2136570034C2780259306 @default.
• W2136570034 hasConceptScore W2136570034C2781413609 @default.
• W2136570034 hasConceptScore W2136570034C526805850 @default.
• W2136570034 hasConceptScore W2136570034C71924100 @default.
• W2136570034 hasConceptScore W2136570034C90924648 @default.
• W2136570034 hasIssue "15" @default.
• W2136570034 hasLocation W21365700341 @default.
• W2136570034 hasLocation W21365700342 @default.
• W2136570034 hasOpenAccess W2136570034 @default.
• W2136570034 hasPrimaryLocation W21365700341 @default.
• W2136570034 hasRelatedWork W2077567025 @default.
• W2136570034 hasRelatedWork W2082769284 @default.
• W2136570034 hasRelatedWork W2314517044 @default.
• W2136570034 hasRelatedWork W2343642485 @default.
• W2136570034 hasRelatedWork W2385947999 @default.
• W2136570034 hasRelatedWork W2417697013 @default.
• W2136570034 hasRelatedWork W3115106807 @default.
• W2136570034 hasRelatedWork W3147101217 @default.
• W2136570034 hasRelatedWork W4229998397 @default.
• W2136570034 hasRelatedWork W4240014961 @default.

• next